Chronic Hepatitis: Aetiology and Current Management

Cooksley W.G.E., Bradbear R.A., Halliday J.W. and Powell L.W. (1984) Chronic Hepatitis: Aetiology and Current Management. Drugs, 27 6: 579-584. doi:10.2165/00003495-198427060-00004

Author Cooksley W.G.E.
Bradbear R.A.
Halliday J.W.
Powell L.W.
Title Chronic Hepatitis: Aetiology and Current Management
Journal name Drugs   Check publisher's open access policy
ISSN 1179-1950
Publication date 1984-01-01
Sub-type Article (original research)
DOI 10.2165/00003495-198427060-00004
Open Access Status Not yet assessed
Volume 27
Issue 6
Start page 579
End page 584
Total pages 6
Subject 2736 Pharmacology (medical)
2307 Health, Toxicology and Mutagenesis
3005 Toxicology
Abstract The entity of chronic hepatitis has long been an enigma, and its treatment confusing. Recent studies have indicated the importance of excluding causes such as drugs, Wilson’s disease and α1-antitrypsin deficiency. After excluding such causes, there are 3 major groups — ‘autoimmune’, hepatitis B, and non-A, non-B (NANB) in all of which an immunological basis for pathogenesis exists. The autoimmune group has been subdivided into a milder type (chronic persistent hepatitis) and a more severe type (chronic active hepatitis) on histological grounds. Corticosteroids are indicated in chronic active hepatitis if cirrhosis or bridging necrosis is present. However, corticosteroids are contraindicated in disease due to the hepatitis B virus where chronic active hepatitis correlates with the presence of replicating virus (serum positive for e antigen, DNA polymerase and HBV-DNA), and in such cases antiviral agents and immunomodulation are being studied. Very little is known about NANB hepatitis in the absence of an assay and there may be more than a single agent. In hepatitis B, the development of serological markers, molecular probes (HBV-DNA), natural animal hepatitis with near-identical viruses, and δ antigen (a virus requiring coinfection with hepatitis B) have all extended our knowledge so dramatically that it is hoped that the enigma of chronic hepatitis will be solved when an assay for NANB hepatitis becomes available.
Q-Index Code C1
Q-Index Status Provisional Code
Institutional Status Unknown

Document type: Journal Article
Sub-type: Article (original research)
Collection: Scopus Import - Archived
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 2 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 1 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Tue, 26 Jul 2016, 12:28:07 EST by System User